Abstract:Pharmacokinetic research at the host-microbe interface has been primarily directed toward effects on drug metabolism, with fewer investigations considering the absorption process. We previously demonstrated that the transcriptional expression of genes encoding intestinal transporters involved in lipid translocation are altered in germ-free and conventionalized mice possessing distinct bile acid signatures. It was consequently hypothesized that microbial bile acid metabolism, which is the deconjugation and dehydroxylation of the bile acid steroid nucleus by gut bacteria, may impact upon drug transporter expression and/or activity and potentially alter drug disposition. Using a panel of three human intestinal cell lines (Caco-2, T84, and HT-29) that differ in basal transporter expression level, bile acid conjugation-, and hydroxylation-status was shown to influence the transcription of genes encoding several major influx and efflux transporter proteins. We further investigated if these effects on transporter mRNA would translate to altered drug disposition and activity. The results demonstrated that the conjugation and hydroxylation status of the bile acid steroid nucleus can influence the cellular response to multidrug resistance (MDR) substrates, a finding that did not directly correlate with directionality of gene or protein expression. In particular, we noted that the cytotoxicity of cyclosporine A was significantly augmented in the presence of the unconjugated bile acids deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) in P-gp positive cell lines, as compared to their taurine/glycine-conjugated counterparts, implicating P-gp in the molecular response. Overall this work identifies a novel mechanism by which gut microbial metabolites may influence drug accumulation and suggests a potential role for the microbial bile acid-deconjugating enzyme bile salt hydrolase (BSH) in ameliorating multidrug resistance through the generation of bile acid species with the capacity to access and inhibit P-gp ATPase. The physicochemical property of nonionization is suggested to underpin the preferential ability of unconjugated bile acids to attenuate the efflux of P-gp substrates and to sensitize tumorigenic cells to cytotoxic therapeutics in vitro. This work provides new impetus to investigate whether perturbation of the gut microbiota, and thereby the bile acid component of the intestinal metabolome, could alter drug pharmacokinetics in vivo. These findings may additionally contribute to the development of less toxic P-gp modulators, which could overcome MDR.

High-throughput transcriptomics of 409 bacteria–drug pairs reveals drivers of gut microbiota perturbation

Simvastatin induces human gut bacterial cell surface genes

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

Extensive impact of non-antibiotic drugs on human gut bacteria

Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs

Emergence of community behaviors in the gut microbiota upon drug treatment

Interplays between drugs and the gut microbiome

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study

Mapping human microbiome drug metabolism by gut bacteria and their genes

The metabolic effect of gut microbiota on drugs

A critical need for 'gut neutrality': mitigating adverse drug–microbiome interactions

Gut Microbiota-Mediated Bile Acid Transformations Alter the Cellular Response to Multidrug Resistant Transporter Substrates in Vitro: Focus on P-glycoprotein

Nutrient Competition Predicts Gut Microbiome Restructuring under Drug Perturbations

Systematic mapping of drug metabolism by the human gut microbiome

Human Gut Microbiota and Drug Metabolism

Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response

Unveiling gut microbiota's role: Bidirectional regulation of drug transport for improved safety

Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1

Interaction between drugs and the gut microbiome

The role of the human gut microbiota in colonization and infection with multidrug-resistant bacteria

Gut microbiome and inflammation in cardiovascular drug response: trends in therapeutic success and commercial focus